$12 Billion is the total value of Baker Brothers Advisors's 130 reported holdings in Q1 2015. The portfolio turnover from Q4 2014 to Q1 2015 was 24.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PCYC | Sell | Pharmacyclics Inc. | $2,313,699,000 | +107.3% | 9,039,652 | -1.0% | 19.24% | +68.9% |
| INCY | Incyte Corp. | $1,360,744,000 | +25.4% | 14,845,559 | 0.0% | 11.32% | +2.2% | |
| GEVA | Buy | Synageva Biopharma Corp. | $1,137,242,000 | +15.0% | 11,660,432 | +9.4% | 9.46% | -6.3% |
| SGEN | Buy | Seattle Genetics, Inc. | $1,020,792,000 | +14.0% | 28,876,712 | +3.6% | 8.49% | -7.1% |
| Sell | Salix Pharmaceuticals Inc. 2.75% 5/15/15conv bonds | $801,152,000 | +47.6% | 216,077,000 | -1.5% | 6.66% | +20.3% | |
| ACAD | Acadia Pharmaceuticals Inc. | $667,490,000 | +2.6% | 20,481,442 | 0.0% | 5.55% | -16.3% | |
| BMRN | Buy | Biomarin Pharmaceuticals Inc. | $523,461,000 | +55.9% | 4,200,456 | +13.1% | 4.35% | +27.0% |
| Incyte Corp. Notes 1.25% 11/15/2020 144Aconv bonds | $508,427,000 | +20.6% | 274,500,000 | 0.0% | 4.23% | -1.7% | ||
| Incyte Corp. Notes 0.375% 11/15/2018 144Aconv bonds | $471,944,000 | +21.6% | 259,000,000 | 0.0% | 3.92% | -0.9% | ||
| Incyte Corp. Notes 4.75% 10/1/2015 144Aconv bonds | $421,673,000 | +25.4% | 40,446,000 | 0.0% | 3.51% | +2.2% | ||
| GHDX | Buy | Genomic Health Inc. | $417,220,000 | -4.4% | 13,656,942 | +0.0% | 3.47% | -22.1% |
| ANAC | Anacor Pharmaceuticals Inc. | $243,242,000 | +79.4% | 4,204,702 | 0.0% | 2.02% | +46.2% | |
| Sell | Biomarin Pharmaceuticals Inc. Notes 1.875% 4/23/2017conv bonds | $136,987,000 | +34.2% | 22,379,000 | -2.3% | 1.14% | +9.3% | |
| NVTA | New | Invitae Corp. | $109,861,000 | – | 6,554,967 | +100.0% | 0.91% | – |
| ONCE | New | Spark Therapeutics, Inc. | $102,878,000 | – | 1,327,451 | +100.0% | 0.86% | – |
| DYAX | Sell | Dyax Corp. | $100,890,000 | +16.5% | 6,021,485 | -2.2% | 0.84% | -5.1% |
| BLCM | Sell | Bellicum Pharmaceuticals, Inc. | $97,096,000 | -1.6% | 4,190,594 | -2.2% | 0.81% | -19.8% |
| BCRX | Sell | Biocryst Pharmaceuticals Inc. | $94,618,000 | -27.4% | 10,478,204 | -2.2% | 0.79% | -40.8% |
| Sell | Gilead Sciences Inc. 1.625% 5/1/16conv bonds | $90,193,000 | +1.4% | 20,944,000 | -2.6% | 0.75% | -17.4% | |
| Sell | Medivation Inc. 2.625% 4/1/17conv bonds | $84,927,000 | +26.1% | 33,889,000 | -2.4% | 0.71% | +2.8% | |
| MRTX | Buy | Mirati Therapeutics Inc. | $82,245,000 | +86.6% | 2,805,074 | +17.9% | 0.68% | +52.0% |
| Sell | Acorda Therapeutics Inc. Notes 1.75% 6/15/2021conv bonds | $60,762,000 | -13.0% | 59,583,000 | -2.2% | 0.50% | -29.2% | |
| CERS | Buy | Cerus Corp. | $56,517,000 | -22.6% | 13,553,275 | +15.8% | 0.47% | -36.9% |
| VSAR | Buy | Versartis Inc. | $54,694,000 | +6.8% | 2,977,396 | +30.5% | 0.46% | -13.0% |
| XOMA | Sell | Xoma Corp. | $53,539,000 | -11.9% | 14,708,613 | -13.1% | 0.44% | -28.2% |
| XNPT | Sell | Xenoport Inc. | $46,341,000 | -23.5% | 6,508,622 | -5.7% | 0.38% | -37.7% |
| ARRY | Buy | Array Biopharma Inc. | $41,705,000 | +514.9% | 5,658,755 | +294.7% | 0.35% | +402.9% |
| Sell | Salix Pharmaceuticals Inc. 1.5% 3/15/19conv bonds | $38,948,000 | +42.5% | 14,668,000 | -2.2% | 0.32% | +16.1% | |
| HRTX | Heron Therapeutics, Inc. | $37,943,000 | +44.6% | 2,607,784 | 0.0% | 0.32% | +17.9% | |
| DBVT | DBV Technologies Inc.sponsored adr | $35,489,000 | -13.9% | 1,519,229 | 0.0% | 0.30% | -29.9% | |
| INSM | Buy | Insmed Inc. | $32,937,000 | +92.2% | 1,583,490 | +42.9% | 0.27% | +56.6% |
| CPRX | Buy | Catalyst Pharmaceuticals, Inc. | $32,758,000 | +64.2% | 7,565,462 | +12.7% | 0.27% | +33.3% |
| HALO | Sell | Halozyme Therapeutics Inc. | $32,104,000 | +19.8% | 2,248,152 | -19.0% | 0.27% | -2.2% |
| TGTX | TG Therapeutics Inc. | $31,739,000 | -2.3% | 2,050,313 | 0.0% | 0.26% | -20.2% | |
| DSCI | Sell | Derma Sciences Inc. | $29,288,000 | -11.1% | 3,457,841 | -2.2% | 0.24% | -27.4% |
| PGNX | Sell | Progenics Pharmaceuticals, Inc. | $26,018,000 | -22.7% | 4,350,808 | -2.2% | 0.22% | -37.0% |
| IDRA | Buy | Idera Pharmaceuticals Inc. | $25,842,000 | +259.9% | 6,965,432 | +327.8% | 0.22% | +194.5% |
| ALDR | Buy | Alder Biopharmaceuticals Inc. | $25,385,000 | +469.0% | 879,581 | +473.6% | 0.21% | +358.7% |
| ACOR | Sell | Acorda Therapeutics, Inc. | $24,591,000 | -20.4% | 738,916 | -2.2% | 0.20% | -34.9% |
| GILD | Sell | Gilead Sciences Inc. | $24,532,000 | +1.6% | 249,995 | -2.4% | 0.20% | -17.1% |
| SGMO | Buy | Sangamo Biosciences, Inc. | $22,023,000 | +51.6% | 1,404,544 | +47.0% | 0.18% | +23.6% |
| NBIX | Sell | Neurocrine Biosciences, Inc. | $21,532,000 | +73.8% | 542,236 | -2.2% | 0.18% | +42.1% |
| Sell | Biomarin Pharmaceuticals Inc. Notes 0.75% 10/15/2018conv bonds | $17,970,000 | +22.1% | 12,228,000 | -2.2% | 0.15% | -0.7% | |
| KYTH | Buy | Kythera Biopharmaceuticals Inc. | $17,766,000 | +79.0% | 354,265 | +23.8% | 0.15% | +46.5% |
| BLUE | Sell | Bluebird Bio Inc. | $17,703,000 | +28.7% | 146,581 | -2.3% | 0.15% | +5.0% |
| RPRX | Repros Therapeutics Inc. | $17,180,000 | -13.8% | 2,000,000 | 0.0% | 0.14% | -29.9% | |
| FOMX | Buy | Foamix Pharmaceuticals Ltd. | $16,853,000 | +135.3% | 1,821,967 | +78.3% | 0.14% | +91.8% |
| VNDA | Sell | Vanda Pharmaceuticals, Inc. | $16,277,000 | -74.6% | 1,750,230 | -60.9% | 0.14% | -79.4% |
| NVAX | Buy | Novavax Inc. | $16,091,000 | +121.8% | 1,945,687 | +59.0% | 0.13% | +81.1% |
| LBIO | New | Lion Biotechnologies Inc. | $16,046,000 | – | 1,325,000 | +100.0% | 0.13% | – |
| CLVS | Clovis Oncology Inc. | $15,041,000 | +32.6% | 202,630 | 0.0% | 0.12% | +7.8% | |
| AGIO | Sell | Agios Pharmaceuticals Inc. | $14,141,000 | -22.8% | 149,954 | -8.2% | 0.12% | -36.9% |
| OMER | Sell | Omeros Corp. | $14,043,000 | -12.6% | 637,446 | -1.6% | 0.12% | -28.7% |
| XNCR | Buy | Xencor Inc. | $13,360,000 | +40.8% | 872,072 | +47.5% | 0.11% | +14.4% |
| THLD | Buy | Threshold Pharmaceuticals Inc. | $11,878,000 | +73.3% | 2,925,519 | +35.7% | 0.10% | +41.4% |
| ADHD | Buy | Alcobra Ltd. | $10,077,000 | +832.2% | 1,789,871 | +517.5% | 0.08% | +663.6% |
| AQXP | Sell | Aquinox Pharmaceuticals, Inc. | $9,763,000 | +7.5% | 1,187,666 | -1.9% | 0.08% | -12.9% |
| MGNX | Sell | Macrogenics, Inc. | $9,569,000 | -12.5% | 305,043 | -2.2% | 0.08% | -28.6% |
| AERI | Aerie Pharmaceuticals Inc. | $9,382,000 | +7.4% | 299,356 | 0.0% | 0.08% | -12.4% | |
| RARE | Sell | Ultragenyx Pharmaceuticals Inc. | $9,245,000 | +40.5% | 148,894 | -0.7% | 0.08% | +14.9% |
| IMGN | New | Immunogen, Inc. | $8,945,000 | – | 999,496 | +100.0% | 0.07% | – |
| PRQR | ProQR Therapeutics NV | $8,752,000 | +1.0% | 400,000 | 0.0% | 0.07% | -17.0% | |
| OSIR | Sell | Osiris Therapeutics Inc. | $8,776,000 | +7.5% | 499,193 | -2.2% | 0.07% | -12.0% |
| ARWR | Buy | Arrowhead Research Corp. | $8,728,000 | -3.9% | 1,290,187 | +4.8% | 0.07% | -21.5% |
| SNSS | Sunesis Pharmaceuticals, Inc. | $7,840,000 | -3.9% | 3,200,000 | 0.0% | 0.06% | -21.7% | |
| LJPC | Sell | La Jolla Pharmaceuticals, Co. | $7,540,000 | -3.1% | 412,008 | -2.3% | 0.06% | -20.3% |
| CNCE | Sell | Concert Pharmaceuticals, Inc. | $7,511,000 | +11.6% | 495,908 | -1.9% | 0.06% | -10.1% |
| CLDN | Sell | Celladon Corp | $6,947,000 | -5.1% | 366,806 | -2.2% | 0.06% | -22.7% |
| KPTI | Buy | Karyopharm Therapeutics Inc. | $6,642,000 | +88.6% | 216,990 | +130.6% | 0.06% | +52.8% |
| FMI | Sell | Foundation Medicine Inc. | $5,978,000 | +113.3% | 124,255 | -1.5% | 0.05% | +72.4% |
| JUNO | Juno Therapeutics Inc. | $6,066,000 | +16.2% | 100,000 | 0.0% | 0.05% | -5.7% | |
| LGND | Sell | Ligand Pharmaceuticals Inc. | $5,659,000 | +44.9% | 73,386 | -0.0% | 0.05% | +17.5% |
| RXDX | Ignyta Inc. | $5,681,000 | +45.3% | 571,000 | 0.0% | 0.05% | +17.5% | |
| TTHI | New | Transition Therapeutics, Inc. | $5,254,000 | – | 769,230 | +100.0% | 0.04% | – |
| AMRN | New | Amarin Corp. PLCsponsored adr | $5,161,000 | – | 2,205,710 | +100.0% | 0.04% | – |
| STML | Sell | Stemline Therapeutics Inc. | $4,826,000 | -16.5% | 333,497 | -1.5% | 0.04% | -32.2% |
| CYTR | Sell | Cytrx Corp. | $4,448,000 | +20.2% | 1,319,989 | -2.2% | 0.04% | -2.6% |
| CMRX | Sell | Chimerix Inc. | $4,342,000 | -37.4% | 115,216 | -33.2% | 0.04% | -49.3% |
| EPZM | Buy | Epizyme Inc. | $4,366,000 | +14.6% | 232,481 | +15.1% | 0.04% | -7.7% |
| INFI | Sell | Infinity Pharmaceuticals Inc. | $4,264,000 | -19.1% | 305,037 | -2.2% | 0.04% | -35.2% |
| DSCO | Sell | Discovery Laboratories Inc. | $4,248,000 | +0.3% | 3,569,643 | -2.3% | 0.04% | -18.6% |
| RCPT | Receptos Inc. | $3,941,000 | +34.6% | 23,900 | 0.0% | 0.03% | +10.0% | |
| New | Array Biopharma, Inc. Notes 3.0% 6/1/2020conv bonds | $3,759,000 | – | 3,000,000 | +100.0% | 0.03% | – | |
| ZFGN | New | Zafgen, Inc. | $3,753,000 | – | 94,745 | +100.0% | 0.03% | – |
| SAGE | Sage Therapeutics Inc. | $3,767,000 | +37.2% | 75,000 | 0.0% | 0.03% | +10.7% | |
| ISIS | Sell | Isis Pharmaceuticals, Inc. | $3,638,000 | -38.8% | 57,140 | -40.7% | 0.03% | -50.8% |
| ASMB | New | Assembly Biosciences, Inc. | $3,310,000 | – | 250,000 | +100.0% | 0.03% | – |
| Neuroderm Ltd. | $3,355,000 | -4.4% | 250,000 | 0.0% | 0.03% | -22.2% | ||
| LPCN | Sell | Lipocine Inc. | $3,375,000 | +28.3% | 489,175 | -2.2% | 0.03% | +3.7% |
| BLPH | New | Bellerophon Therapeutics, Inc. | $3,213,000 | – | 350,000 | +100.0% | 0.03% | – |
| TKMR | Sell | Tekmira Pharmaceuticals Corp. | $3,153,000 | -57.0% | 180,582 | -62.7% | 0.03% | -65.3% |
| ZGNX | Sell | Zogenix, Inc. | $3,149,000 | -2.2% | 2,298,466 | -2.2% | 0.03% | -21.2% |
| AUPH | Sell | Aurinia Pharmaceuticals, Inc. | $3,118,000 | +20.0% | 711,499 | -2.2% | 0.03% | -3.7% |
| IRWD | Sell | Ironwood Pharmaceuticals Inc. | $2,707,000 | -49.0% | 169,163 | -51.1% | 0.02% | -57.4% |
| BDSI | Buy | BioDelivery Sciences Intl. Inc. | $2,686,000 | +6.4% | 255,866 | +21.8% | 0.02% | -15.4% |
| Protalix Biotherapeutics, Inc. Notes 4.5% 9/15/18conv bonds | $2,612,000 | -1.2% | 3,500,000 | 0.0% | 0.02% | -18.5% | ||
| AFMD | Affimed N.V. | $2,520,000 | +1.6% | 400,000 | 0.0% | 0.02% | -16.0% | |
| ITCI | New | Intra Cellular Therapies Inc. | $2,487,000 | – | 104,166 | +100.0% | 0.02% | – |
| ASPX | New | Auspex Pharmaceuticals, Inc. | $2,507,000 | – | 25,000 | +100.0% | 0.02% | – |
| MSTX | Sell | Mast Therapeutics, Inc. | $2,283,000 | -14.6% | 4,707,464 | -1.4% | 0.02% | -29.6% |
| ENTA | Enanta Pharmaceuticals Inc. | $2,307,000 | -39.8% | 75,357 | 0.0% | 0.02% | -51.3% | |
| ACHN | Sell | Achillion Pharmaceuticals, Inc. | $2,112,000 | -60.7% | 214,237 | -51.1% | 0.02% | -67.3% |
| VTAE | New | Vitae Pharmaceuticals Inc. | $2,197,000 | – | 187,597 | +100.0% | 0.02% | – |
| ZIOP | Sell | Ziopharm Oncology Inc. | $2,038,000 | +107.5% | 189,259 | -2.3% | 0.02% | +70.0% |
| BOTA | Sell | Biota Pharmaceuticals Inc. | $1,985,000 | -19.9% | 863,184 | -22.0% | 0.02% | -32.0% |
| PRTO | Proteon Therapeutics, Inc. | $2,011,000 | +11.8% | 172,917 | 0.0% | 0.02% | -5.6% | |
| PTN | Palatin Technologies Inc. | $2,091,000 | +39.7% | 2,050,000 | 0.0% | 0.02% | +13.3% | |
| MRNS | Sell | Marinus Pharmaceuticals Inc. | $1,798,000 | -16.8% | 200,000 | -2.2% | 0.02% | -31.8% |
| ASND | New | Ascendis Pharma SAsponsored adr | $1,735,000 | – | 100,000 | +100.0% | 0.01% | – |
| OPHT | Sell | Ophthotech Corp. | $1,659,000 | +0.5% | 35,649 | -3.1% | 0.01% | -17.6% |
| MDWD | Mediwound Ltd. | $1,629,000 | +8.7% | 225,000 | 0.0% | 0.01% | -6.7% | |
| CLLS | New | Cellectis SAsponsored adr | $1,729,000 | – | 50,000 | +100.0% | 0.01% | – |
| DERM | Dermira Inc. | $1,535,000 | -15.2% | 100,000 | 0.0% | 0.01% | -27.8% | |
| OSUR | Sell | Orasure Technologies Inc. | $1,500,000 | -36.9% | 229,397 | -2.2% | 0.01% | -50.0% |
| ALDX | New | Aldeyra Therapeutics, Inc. | $1,446,000 | – | 142,000 | +100.0% | 0.01% | – |
| RIGL | Sell | Rigel Pharmaceuticals Inc. | $1,275,000 | +16.5% | 357,187 | -25.9% | 0.01% | 0.0% |
| ALNY | Sell | Alnylam Pharmaceuticals, Inc. | $1,184,000 | +5.2% | 11,340 | -2.2% | 0.01% | -9.1% |
| LOXO | Loxo Oncology Inc. | $1,245,000 | +6.0% | 100,000 | 0.0% | 0.01% | -16.7% | |
| XLRN | Acceleron Pharma Inc. | $1,095,000 | -2.3% | 28,765 | 0.0% | 0.01% | -18.2% | |
| AKAOQ | Achaogen Inc. | $976,000 | -25.2% | 100,000 | 0.0% | 0.01% | -38.5% | |
| SNTA | Sell | Synta Pharmaceuticals Corp. | $949,000 | -28.4% | 489,053 | -2.2% | 0.01% | -42.9% |
| OHRP | New | Ohr Pharmaceuticals, Inc. | $941,000 | – | 370,370 | +100.0% | 0.01% | – |
| QURE | Sell | UniQure N.V. | $730,000 | +60.8% | 30,000 | -2.2% | 0.01% | +20.0% |
| FPRX | Sell | Five Prime Therapeutics Inc. | $440,000 | -17.8% | 19,247 | -2.9% | 0.00% | -20.0% |
| AEGR | New | Aegerion Pharmaceuticals, Inc. | $374,000 | – | 14,300 | +100.0% | 0.00% | – |
| CCXI | Sell | Chemocentryx Inc. | $370,000 | +8.2% | 49,064 | -1.9% | 0.00% | 0.0% |
| Sell | Aptose Biosciences, Inc. | $181,000 | -93.6% | 33,397 | -93.0% | 0.00% | -93.1% | |
| CYCCP | Cyclacel Pharmaceuticals Inc.pfd conv ex 6% | $86,000 | +4.9% | 13,253 | 0.0% | 0.00% | 0.0% | |
| BIOD | New | Biodel Inc. | $36,000 | – | 30,179 | +100.0% | 0.00% | – |
| BTXWS | Sell | Biotime Inc.warrants | $40,000 | +81.8% | 20,084 | -2.1% | 0.00% | – |
| AST | Exit | Asterias Biotherapeutics, Inc. | $0 | – | -16,775 | -100.0% | -0.00% | – |
| TSRO | Exit | Tesaro Inc. | $0 | – | -31,218 | -100.0% | -0.01% | – |
| GERN | Exit | Geron Corp. | $0 | – | -402,629 | -100.0% | -0.01% | – |
| SGYPQ | Exit | Synergy Pharmaceuticals | $0 | – | -973,245 | -100.0% | -0.03% | – |
| CLTX | Exit | Celsus Therapeuticssponsored adr ne | $0 | – | -673,887 | -100.0% | -0.03% | – |
| FOLD | Exit | Amicus Therapeutics | $0 | – | -481,697 | -100.0% | -0.04% | – |
| MNKKQ | Exit | Mallinckrodt PUB LTD CO | $0 | – | -46,666 | -100.0% | -0.05% | – |
| QLTI | Exit | QLT Inc. | $0 | – | -1,535,863 | -100.0% | -0.06% | – |
| SLXP | Exit | Salix Pharmaceuticals | $0 | – | -635,321 | -100.0% | -0.74% | – |
| AVNR | Exit | Avanir Pharmaceuticals | $0 | – | -38,513,713 | -100.0% | -6.66% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-05-15
About Baker Brothers Advisors
Baker Brothers Advisors is a well-known investment management firm that specializes in the healthcare sector. The firm was founded in 2000 by brothers Julian and Felix Baker, who are both highly respected in the industry. Julian Baker is the CEO of the firm, while Felix Baker serves as a managing partner.
Baker Brothers Advisors has a reputation for investing in innovative healthcare companies that have the potential to make a significant impact on the industry. The firm has a long-term investment approach and is known for taking large positions in companies that it believes in. Some of the firm's most successful investments include companies such as Pharmacyclics, which was acquired by AbbVie for $21 billion, and Ariad Pharmaceuticals, which was acquired by Takeda for $5.2 billion.
The firm's investment strategy is led by its Chief Investment Officer, Dr. Robert Duggan, who has a background in both medicine and finance. Dr. Duggan is known for his ability to identify promising healthcare companies and for his willingness to take risks on early-stage companies.
Overall, Baker Brothers Advisors is a highly respected investment management firm that has a proven track record of success in the healthcare sector. While the firm's investment approach may not be suitable for all investors, those who are interested in the healthcare sector may want to consider Baker Brothers Advisors as a potential investment opportunity.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Incyte Corporation | 42 | Q3 2023 | 37.6% |
| ACADIA Pharmaceuticals Inc. | 42 | Q3 2023 | 10.9% |
| Biomarin Pharmaceuticals Inc. | 42 | Q3 2023 | 5.9% |
| BioCryst Pharmaceuticals, Inc. | 42 | Q3 2023 | 1.7% |
| Cerus Corporation | 42 | Q3 2023 | 0.9% |
| Insmed Incorporated | 42 | Q3 2023 | 0.4% |
| Mirati Therapeutics, Inc. | 41 | Q3 2023 | 1.8% |
| Bluebird Bio Inc. | 41 | Q3 2023 | 0.3% |
| Heron Therapeutics, Inc. | 39 | Q3 2023 | 1.5% |
| ChemoCentryx, Inc. | 37 | Q3 2022 | 0.6% |
View Baker Brothers Advisors's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Neoleukin Therapeutics, Inc. | August 17, 2023 | 9,469,838 | 20.0% |
| Mereo Biopharma Group plc | August 10, 2023 | 14,604,391 | 2.2% |
| Verastem, Inc. | August 10, 2023 | ? | ? |
| TScan Therapeutics, Inc. | June 02, 2023 | 2,793,938 | 6.5% |
| ACADIA PHARMACEUTICALS INC | May 24, 2023 | 43,084,280 | 26.5% |
| INCYTE CORP | March 15, 2023 | 36,280,967 | 16.3% |
| Seagen Inc. | March 13, 2023 | 46,985,656 | 25.1% |
| Talis Biomedical Corp | March 10, 2023 | 37,569,140 | 66.2% |
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 6,384,013 | 9.9% |
| Merus N.V. | February 14, 2023 | ? | ? |
View Baker Brothers Advisors's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-23 |
| SC 13D/A | 2024-04-23 |
| 4 | 2024-04-22 |
| 3 | 2024-04-18 |
| SC 13D | 2024-04-18 |
| 3 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| SC 13D | 2024-04-01 |
View Baker Brothers Advisors's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.